title: Results and prognostic factors following optimal treatment of advanced Hodgkin's disease.
authors: Memorial Sloan Kettering Cancer Center, New York, NY 10021.
authors: D J
authors: DJ
authors: Straus
authors: J
authors: J
authors: Gaynor
authors: J
authors: J
authors: Myers
authors: D
authors: D
authors: Merke
authors: D
authors: D
authors: Chapman
authors: J
authors: J
authors: Caravelli
authors: L Z
authors: LZ
authors: Nisce
authors: B J
authors: BJ
authors: Lee
authors: B D
authors: BD
authors: Clarkson
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008466:Mechlorethamine / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D008130:Lomustine; D003606:Dacarbazine; D004317:Doxorubicin; D008558:Melphalan; D014751:Vindesine; D011241:Prednisone